Gemcitabine

Generic Name: Gemcitabine

Brand Names: Gemzar

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₁F_₂N_₃O_₄

CAS Number: 95058-81-4

Unique Ingredient Identifier: B76N6SBZ8R

Background: Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, gemcitabine is transformed into its active metabolites that wor...

Indication: Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents.

In combination with carboplatin, it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
...

Associated Conditions: Advanced Ovarian Cancer, Bladder Transitional Cell Carcinoma Stage IV, Carcinoma of the Head and Neck, Cervical Cancer, Cutaneous T-Cell Lymphoma (CTCL), Hodgkins Disease (HD), Mesothelioma, Metastatic Breast Cancer, Pancreatic Adenocarcinoma Locally Advanced, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer (NSCLC), Stage 4 Pancreatic adenocarcinoma

Associated Therapies: -

Clinical Trials

Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer

Phase 1

Completed

Conditions: Carcinoma, Transitional Cell

First Posted Date: 2005-01-17

Last Posted Date: 2006-08-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 61

Registration Number: NCT00101842

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Dallas, Texas, United States

S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: gemcitabine
Drug: paclitaxel

First Posted Date: 2005-01-07

Last Posted Date: 2012-10-01

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 67

Registration Number: NCT00100789

Locations: 🇺🇸
Holland Community Hospital, Holland, Michigan, United States
🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
St. John's Regional Health Center, Springfield, Missouri, United States

and more 119 locations

A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2

Completed

Conditions: Peritoneal Cancer
Fallopian Tube Cancer
Ovarian Cancer

Interventions: Drug: Placebo
Drug: Gemcitabine
Drug: Pertuzumab

First Posted Date: 2004-11-18

Last Posted Date: 2015-06-10

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 131

Registration Number: NCT00096993

Locations: 🇺🇸
Carle Clinic Association, Urbana, Illinois, United States
🇺🇸
Franklin Square Hospital Center, Baltimore, Maryland, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 38 locations

Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Cyclophosphamide
Drug: Paclitaxel
Drug: Docetaxel
Drug: Gemcitabine
Drug: Doxorubicin

First Posted Date: 2004-10-08

Last Posted Date: 2018-01-11

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 4894

Registration Number: NCT00093795

Locations: 🇺🇸
Chestnut Hill Healthcare Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Altru Cancer Center at Altru Hospital, Grand Forks, North Dakota, United States
🇺🇸
Providence Cancer Center, Anchorage, Alaska, United States

and more 9 locations

S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: cisplatin
Drug: gemcitabine
Drug: docetaxel
Drug: paclitaxel
Drug: vinorelbine

First Posted Date: 2004-09-13

Last Posted Date: 2012-10-08

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 204

Registration Number: NCT00003587

Locations: 🇺🇸
CCOP - Montana Cancer Consortium, Billings, Montana, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

and more 81 locations

A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non Small Cell Lung Carcinoma

Interventions: Drug: pemetrexed
Drug: gemcitabine
Drug: cisplatin

First Posted Date: 2004-07-16

Last Posted Date: 2019-09-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1713

Registration Number: NCT00087711

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sutton, United Kingdom

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

Phase 2

Active, not recruiting

Conditions: Urethral Cancer
Urachal Cancer
Bladder Cancer

Interventions: Drug: 5-Fluorouracil (5-FU)
Drug: Leucovorin
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2004-05-19

Last Posted Date: 2024-05-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 46

Registration Number: NCT00082706

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer

Phase 2

Completed

Conditions: Stage IVA Gallbladder Cancer
Stage II Gallbladder Cancer
Stage IIIA Gallbladder Cancer
Stage IVB Gallbladder Cancer
Stage IIIB Gallbladder Cancer

Interventions: Drug: triapine
Drug: gemcitabine

First Posted Date: 2004-01-12

Last Posted Date: 2015-09-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 33

Registration Number: NCT00075504

Locations: 🇺🇸
Montefiore Medical Center, Bronx, New York, United States

Intrathecal Gemcitabine to Treat Neoplastic Meningitis, IT Gemcitabine

Phase 1

Terminated

Conditions: Meningitis
Neoplasms

Interventions: Drug: Gemcitabine

First Posted Date: 2003-12-18

Last Posted Date: 2012-11-12

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 10

Registration Number: NCT00074607

Locations: 🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
National Cancer Institute, Bethesda, Maryland, United States

and more 2 locations

Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Withdrawn

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-11-06

Last Posted Date: 2013-07-10

Lead Sponsor: Daiichi Pharmaceuticals

Registration Number: NCT00072228

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States
🇺🇸
University of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy